Physician profile
Gregory A Monroe
NPI 1598735557
$2,148.28
in general payments reported to CMS, 2019-2025
28 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $67.42 · 2023: $646 · 2024: $816 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $412.68 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $194.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $172.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $160.70 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $153.45 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.38 | 2023-2024 | |
| Amgen INC. | $108.64 | 2023-2025 | Otezla, Repatha, Repatha |
| Ucb, INC. | $104.01 | 2023-2024 | Nayzilam, Briviact |
| E.R. Squibb & Sons, L.L.C. | $92.18 | 2019-2025 | Eliquis |
| Abbvie INC. | $84.79 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.85 | 2019-2024 | Ofev |
| Abbott Laboratories | $53.78 | 2023-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $45.20 | 2020-2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $43.41 | 2023 | Quviviq |
| Exact Sciences Corporation | $43.03 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.34 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $32.62 | 2023 | Gemtesa |
| Vanda Pharmaceuticals INC. | $32.23 | 2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $28.65 | 2019 | |
| Neurelis, INC. | $25.99 | 2025 | Valtoco |
| Lundbeck LLC | $21.06 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $20.92 | 2023 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.32 | 2024 | Xifaxan |
| Sanofi Pasteur INC. | $20.01 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.58 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $14.65 | 2024 | Rexulti |
| Acadia Pharmaceuticals INC | $13.77 | 2024 | Nuplazid |
| Astellas Pharma US INC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Monroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.